Related Experiment Video
Updated: Aug 14, 2026
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats
1Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-12 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Abstract:
1. In the present study, we investigated the preventive effects of pirfenidone (PFD), an antifibrotic agent, on experimental hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats. 2. Treatment with DMN caused a significant decrease in bodyweight and liver weight. Oral PFD (500 mg/kg daily for 4 weeks) essentially prevented this DMN-induced loss in bodyweight and tended to suppress the loss in liver weight. There were no significant differences in liver weight and serum L-alanine aminotransferase levels between PFD-treated and -untreated groups. Pirfenidone has no major side effects in vivo. 3. Pirfenidone suppressed the induction of hepatic fibrosis determined by histological evaluation and reduced hepatic hydroxyproline levels. Expression of mRNA for type I collagen and transforming growth factor-beta in the liver was also suppressed by PFD treatment. 4. Because hepatic stellate cells (HSC) are the major cellular source of extracellular matrix in hepatic fibrosis, we examined the effects of PFD on type I collagen production in vitro using rat primary HSC cultures. Pirfenidone inhibited collagen production in HSC culture in a dose-dependent manner. 5. These results demonstrate that the inhibitory effects of PFD against hepatic fibrosis may be due, at least in part, to blockade of collagen production by HSC and suggest that PFD may be potentially useful in the prevention of the development of hepatic fibrosis.
Insights
Pirfenidone (PFD) prevents liver fibrosis in rats by inhibiting collagen production in hepatic stellate cells. This antifibrotic agent shows potential for preventing hepatic fibrosis development.
Area of Science:
- Pharmacology
- Hepatology
- Fibrosis Research
Background:
- Hepatic fibrosis is a significant health concern.
- Dimethylnitrosamine (DMN) is a known inducer of experimental liver fibrosis.
- Antifibrotic agents are crucial for managing liver disease.
Purpose of the Study:
- To investigate the preventive effects of pirfenidone (PFD) on DMN-induced hepatic fibrosis in rats.
- To elucidate the mechanism by which PFD exerts its antifibrotic effects.
Main Methods:
- Rats were treated with DMN to induce liver fibrosis.
- Oral administration of PFD (500 mg/kg daily for 4 weeks) was assessed.
- Histological evaluation, hydroxyproline levels, and gene expression (type I collagen, TGF-β) were analyzed.
- In vitro studies using rat primary hepatic stellate cells (HSCs) were conducted.
Main Results:
- PFD prevented DMN-induced loss in bodyweight and tended to suppress liver weight loss.
- PFD significantly suppressed hepatic fibrosis, reduced hydroxyproline levels, and decreased collagen I and TGF-β mRNA expression.
- In vitro, PFD inhibited collagen production in HSCs in a dose-dependent manner.
- PFD demonstrated no major in vivo side effects.
Conclusions:
- Pirfenidone effectively prevents experimental hepatic fibrosis induced by DMN.
- PFD's antifibrotic effects are partly mediated by blocking collagen production in hepatic stellate cells.
- PFD shows potential as a therapeutic agent for preventing hepatic fibrosis.
